Start your career @sciomics

Sciomics ist ein schnell wachsendes Start-Up-Unternehmen mit dem Fokus auf Proteinanalysen mittels Antikörper-Microarrays. Wir entwickeln Biomarker-Signaturen für eine Frühdiagnose und Patientenstratifizierung bei verschiedenen onkologischen Erkrankungen sowie Organversagen. Ergänzend bietet die Sciomics GmbH ein breites Dienstleistungsspektrum für kundenspezifische Forschungs- und Entwicklungsprojekte auf Basis unserer scioDiscover Plattform.

Wir sind ein junges und engagiertes Team mit engen Kontakten zu namhaften Forschungszentren.

Derzeit haben wir die folgenden Stellen zu besetzen. Da sich dies in einem dynamischen Unternehmen schnell ändern kann, sind uns Initiativbewerbungen an This email address is being protected from spambots. You need JavaScript enabled to view it. willkommen.

zum 01.09.2021 eine(n)

BTA / Biologielaborant /MTA (m/w/d)

unbefristet und flexibel in Teilzeit oder Vollzeit

Preparative work for antibody microarray analysis

Ihre Aufgaben:

Selbstständige Organisation und Bearbeitung eingehender Kundenaufträge
Allgemeine Labororganisation
Planung und Durchführung von Experimenten
Mitarbeit bei der Produkt- und Service-Entwicklung
Dokumentation der Experimente und Analyse der Ergebnisse

Ihr Profil:

Abgeschlossene Ausbildung zum Biologielaborant / CTA / BTA / MTA
Idealerweise Erfahrung mit Proteinanalysen
Sie arbeiten selbstständig und gut strukturiert im Labor
Gute Deutsch- und Englischkenntnisse in Wort und Schrift
Teamfähigkeit, Flexibilität und Kommunikationsfähigkeit zeichnen Sie aus

Haben wir Ihr Interesse geweckt? Dann senden Sie uns bitte Ihre digitalen Bewerbungsunterlagen an This email address is being protected from spambots. You need JavaScript enabled to view it..

scioPhospho: protein profiling and phosphorylation status

scioPhospho combines the advantages of a robust and cost-efficient protein expression profiling using scioDiscover with information on phosphorylation status. This combination provides a comprehensive overview on signalling events and pathway activity regulation. Features 1,300 highly relevant proteins are profiled in a single assay Phosphorylation status combined with protein expression levels…

scioDiscover - Protein Profiling on expression level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioCD - Cell surface marker and Cytokine profiling

Characterise a certain cell type? Cell composition in a certain tissue sample? In-depth profiling of CD-marker expression? Increase your throughput at high sensitivity levels? You aim…

scioUbi

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse up to 1,000 proteins in a single assay. Features Screen…

scioCyto : Cytokine profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or…

New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

| March 2021 | Scientists at Heidelberg University Hospital characterized the protein profile response of an endometrial cell line to Metformin treatment and hyperinsulinemia with our scioDiscover platform:

"The presented data helps identify potential targets affected by metformin treatment in EC and allows for a better understanding of the mechanism of action of the biguanide drug’s anti-cancer activity.

With the presented data, we contribute to a better understanding of the anti-cancer activity of metformin as well as its underlying mechanism of action in EC cells."

Lange, C. et al. (2021) ‘Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line’, PLoS ONE 16(3):e0248103. https://doi.org/10.1371/journal.pone.0248103

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

| Feb 2021 | Scientists at Heidelberg University Hospital used our scioCD platform to profile CD8⁺SLAMF7⁺ cell cultures:

"High throughput screening of 351 different cytokines and immune proteins in the supernatants of the T cells cultures revealed strong upregulation of IL-6, IL-8, both vital survival factors for myeloma cells, and CXCL5, a chemokine that could enhance the frequency of CD4 Treg, in the cultures containing CD8⁺SLAMF7⁺ cells. IL-2 and IL-5 were upregulated in the control cultures without CD8⁺SLAMF7⁺ T cells, highlighting a more activated state in the control group and suggestion IL-6 and IL-8 as potential effector cytokines for the suppressive CD8⁺SLAMF7⁺ T cells."

Awwad, M. H. S. et al. (2021) ‘Selective elimination of immunosuppressive T cells in patients with multiple myeloma’, Leukemia, pp. 1–14. doi: 10.1038/s41375-021-01172-x.

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

| Feb 2021 | Scientists at Rostock University Medical Center used our scioCD platform to Corneal Epithelial Cells stimulated with Alternating Current Electric Fields:

"Analysis of the protein array data revealed that the treatment of cells with AC EFs altered the expression of various protein products ... revealed activation of various diverse cellular signaling pathways in which TNF, MAPK, IL17, and PI3K-Akt signaling pathways were significantly impacted ..."

B. S. Kowtharapu et. al., „Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields“, Genes, Bd. 12, Nr. 2, Art. Nr. 2, Feb. 2021, doi: 10.3390/genes12020299.

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

| Dec 2020 | Scientists at University of Sassari used our scioPhospho platform to to analyse the synergy of BET and PARP inhibition in Small Cell Lung Cancer Cells:

"Among the I-BET762-associated and combination-associated differentially expressed proteins, 150 were common to both treatment conditions. ... Ranking I-BET762-associated and combination-associated DEPs by their differential expression revealed CHEK2 and PTEN to be among the top-downregulated proteins, whose deficiencies have been associated with HR defects and increased PARPi sensitivity. "

Fiorentino, F. P. et al. (2020) ‘BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells’, International Journal of Molecular Sciences, 21(24). doi: 10.3390/ijms21249595.

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

| Jan 2019 | In the article, scientists at Tel Aviv University used our scioDiscover platform to analyse tumor-associated eosinophils in colorectal cancer. The full article is published in Cancer Immunology Research.

Rather like working with committed colleagues than with a company, and we got great data out of the project

Prof. Dr. Andreas Weigert

Goethe-University Frankfurt, Faculty of Medicine, Institute of Biochemistry I, Frankfurt, Germany

"We were under considerable time pressure to gain comprehensive information about cytokine/chemokine levels in a mouse model of self-resolving inflammation. To add to our misery, we had only a small number of biological replicates to run the analyses. Thankfully, the team at Sciomics were able to come to our rescue by providing a very prompt analysis, without neglecting to properly communicate the procedure, potential caveats and other details. The whole process was a very satisfying experience, rather like working with committed colleagues than with a company, and we got great data out of the project. I do happily recommend working with Sciomics for targeted proteomics analyses."

Product: scioCD

7 days ago
Join us at this year's BIO Digital virtual conference and learn how we can push your research forward with our prot… https://t.co/8eKhFB8Hmm
41 days ago
RT @MCDS_Therapy: #DidYouKnow That 25 years have passed and there is STILL no #Treatment for #MCDS? We're working to change that💪 View th…
47 days ago
Sciomics is celebrating its 8th birthday this month, so we decided to add another array to our repertoire: scioCake… https://t.co/OYdtwl872y
62 days ago
Join us at Nordic Life Science Days virtual partnering conference @NLSDays and learn how we can advance your resear… https://t.co/u3eKUmn7G4
67 days ago
#Kudos to Katrin H. from our scientists' team at @sciomics for one year of great work. Here's to many more to come!… https://t.co/E75AnUwLMP

Meet us at BIO Digital 2021

Meet us at SLAS Europe 2021

Start your career @sciomics

BTA / Biologielaborant /MTA (m/w/d)

Ihre Aufgaben:

Ihr Profil:

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioDiscover - Protein Profiling on expression level

scioCD - Cell surface marker and Cytokine profiling

scioUbi

scioCyto : Cytokine profiling

COVID-19 related activities and services

News

New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

Testimonials

Rather like working with committed colleagues than with a company, and we got great data out of the project

Tweets

Meet us at BIO Digital 2021

Meet us at SLAS Europe 2021

Beadcrumbs

Start your career @sciomics

BTA / Biologielaborant /MTA (m/w/d)

Ihre Aufgaben:

Ihr Profil:

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioDiscover - Protein Profiling on expression level

scioCD - Cell surface marker and Cytokine profiling

scioUbi

scioCyto : Cytokine profiling

COVID-19 related activities and services

News

New article | Anti-cancer activity and mechanism of action of metformin in endometrial cancer cells

New article | Selective elimination of immunosuppressive T cells in patients with multiple myeloma

New article | Analysis of the Differential Gene and Protein Expression Profiles of Corneal Epithelial Cells Stimulated with Alternating Current Electric Fields

New article | BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells

New article | Activated Eosinophils Exert Antitumorigenic Activities in Colorectal Cancer

Testimonials

Rather like working with committed colleagues than with a company, and we got great data out of the project

Tweets